Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tecaginlimab · GEN1042

Bispecific antibody · Agonist of CD40 and 4-1BB (CD137) (TNFRSF9) · developed by Genmab

Phase 1/2 Most advanced trial (none active)
GMAB Developer
1 Registered trials

What is Tecaginlimab?

Tecaginlimab (GEN1042) is a humanized, Fc-silenced bispecific agonistic antibody that binds both CD40 and 4-1BB (TNFRSF9) and crosslinks cells expressing them. It activates CD40 signaling in antigen-presenting cells and 4-1BB signaling in T cells to enhance cytotoxic T-lymphocyte responses against tumor cells. It is being studied in non-CNS tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GEN1042
Drug type
Bispecific antibody
Targets
CD40, 4-1BB (CD137) (TNFRSF9)
Mechanism
Agonist of CD40 and 4-1BB (CD137) (TNFRSF9)
Pathways
CD40 signaling, 4-1BB signaling, T-cell costimulation, antigen-presenting cell activation
Therapy area
Oncology
Developer
Genmab (GMAB)
Also in trials of
BNTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
27X2015N23

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05491317 Phase 1/2 Non-CNS Tumor Terminated BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-CNS Tumor

Other drugs acting on CD40 / TNFRSF9

More from Genmab

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the GMAB page.

Follow GMAB, the company behind Tecaginlimab

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.